NICE set to implement proposals that will severely restrict patient access to innovative medicines

15 March 2017

The UK’s National Institute for Health and Clinical Excellence (NICE), in collaboration with NHS England, has decided to propose a dynamic upper-limit for costs per quality adjusted life year (QALY) above which they will not recommend funding for highly specialized technologies (HST) treatments.

The NICE has today released plans that were originally proposed in November 2016, and were widely condemned by patients and industry alike.

However, while NICE have made some improvements to their original proposals, the changes are not enough to prevent a drastic reduction in access to innovative treatments for very rare diseases in England, noted the Genetic Alliance UK.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK